Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Product information and disease descriptionProduct descriptionProduct information

Average sales price and wholesale acquisition cost

2 evidence topics · 3 sources

Summary: estimated monthly and annual cost
  • Price basis: no wholesale acquisition cost (WAC) or list price for adrabetadex (Lembaz) had been published as of 18 November 2026, the date of the latest source; trade press reporting on the approval states that list pricing had not been announced.
  • Dosing basis: per the prescribing information, adrabetadex is supplied as one 900 mg/4.5 mL single-dose vial per carton and is administered intrathecally every two weeks, with an age-based starting dose and upward titration to a weight-based maximum of 600 mg every two weeks (7 kg to less than 12 kg) or 900 mg every two weeks (12 kg or more). Every labeled dose is at or below 900 mg, so each administration uses one vial, assuming a whole vial per administration as the label gives no other basis. Every two weeks is 26 administrations, and therefore 26 vials, per year; the manufacturer's out-of-pocket program terms also cap support at 26 doses per year.
  • Base case: not calculable, because no price has been published.
  • Range: not calculable. With one vial per administration, annual drug cost will equal 26 times the vial price at every labeled dose and weight band, and monthly cost will equal annual cost divided by 12.
  • Rationale for the range: the label varies the dose by age, body weight, audiology results, and dose reductions for ataxia or fatigue, but no labeled dose exceeds the content of one vial, so these sources of variation change the volume administered and leave the number of vials unchanged under the whole-vial assumption.
  • Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.